$39.13
0.080.2%
Últ. Act.: Oct 26, 5:05 PM
Novo Nordisk (NVO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Novo Nordisk (NVO) publicó su última previsión de mayo 6, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $42.39B - $46.24B para el período.
En comparación con la previsión anterior, Novo Nordisk elevado redujo su previsión de ingresos desde un rango anterior de $40.46B - $44.32B.
Novo Nordisk ha emitido 15 actualizaciones de orientación entre el noviembre 2, 2022 y el mayo 6, 2026. During this period, the company raised its outlook 11 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.81 | $0.87 | $0.89 | $0.77 |
| Actual | $0.96 | $1.04 | $1.00 | $1.03 |
| Surprise | +18.6% | +19.3% | +12.4% | +33.4% |
| Revenue | ||||
| Estimate | $11.35B | $11.13B | $12.08B | $11.88B |
| Actual | $12.21B | $15.17B | $12.34B | $11.74B |
| Surprise | +7.57% | +36.3% | +2.11% | -1.14% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.81 | $0.70 | $0.91 | $0.92 |
| Revenue | ||||
| Consensus | $11.39B | $11.96B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $0.96 | $0.81 | 18.6 % |
| Q1 | May 6, 2026 | $1.04 | $0.87 | 19.3 % |
| Q4 | Feb 4, 2026 | $1.00 | $0.89 | 12.4 % |
| Q3 | Nov 5, 2025 | $1.03 | $0.77 | 33.4 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 4, 2026 | $12.21B | $11.35B | 7.57 % |
| Q1 | May 6, 2026 | $15.17B | $11.13B | 36.3 % |
| Q4 | Feb 4, 2026 | $12.34B | $12.08B | 2.11 % |
| Q3 | Nov 5, 2025 | $11.75B | $11.88B | -1.14 % |